Patents by Inventor Patrick C. May

Patrick C. May has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5686476
    Abstract: This invention encompasses methods for the inhibition of Alzheimer's Disease comprising administering to a human in need thereof an effective amount of a compound of Formula I ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.The present invention also provides methods of increasing TGF-.beta. expression in the brain, comprising administering to a human in need thereof an effective amount of a compound of formula 1.The present invention also provides methods of inhibiting the .beta.-amyloid peptide mediated neurotoxicity or inflammatory response associated with Alzheimer's Disease (AD) comprising administering to a human in need thereof an effective amount of a compound of formula 1.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: November 11, 1997
    Assignee: Eli Lilly and Company
    Inventor: Patrick C. May
  • Patent number: 5652259
    Abstract: This invention encompasses methods for the inhibition of Alzheimer's Disease comprising administering to a human in need thereof an effective amount of a compound of Formula I ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.The present invention also provides methods of increasing TGF-.beta. expression in the brain, comprising administering to a human in need thereof an effective amount of a compound of formula 1.The present invention also provides methods of inhibiting the .beta.-amyloid peptide mediated neurotoxicity or inflammatory response associated with Alzheimer's Disease (AD) comprising administering to a human in need thereof an effective amount of a compound of formula 1.
    Type: Grant
    Filed: May 9, 1996
    Date of Patent: July 29, 1997
    Assignee: Eli Lilly and Company
    Inventor: Patrick C. May
  • Patent number: 5552415
    Abstract: This invention encompasses methods for the inhibition of Alzheimer's Disease comprising administering to a human in need thereof an effective amount of a compound of Formula I ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.The present invention also provides methods of increasing TGF-.beta. expression in the brain, comprising administering to a human in need thereof an effective amount of a compound of formula 1.The present invention also provides methods of inhibiting the .beta.-amyloid peptide mediated neurotoxicity or inflammatory response associated with Alzheimer's Disease (AD) comprising administering to a human in need thereof an effective amount of a compound of formula 1.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventor: Patrick C. May